Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지

The Clinical Experiences of B-type Natriuretic Peptide Blood Concentrations for Diagnosis in Congestive Heart Failure

Yoo, Byung-Su;Kim, Woo-Jae;Jung, Hyun-Suk;Kim, Jang-Young;Lee, Seung-Whan;Hwang, Sung-Oh;Yoon, Jung-Han;Choe, Kyung-Hoon

  • Published : 20040700
⟨ Previous Next ⟩

Abstract

Background : B-type natriuretic peptide (BNP) has been used as a standard diagnostic tool to define heart failure. The aim of this study was to evaluate the clinical experiences of BNP levels based on a large clinical database. Methods : From Oct. 2002 to July 2003, 3830 patients were analyzed. The patients were divided into the 3 groups: control, systolic (SHF) and diastolic heart failure (DHF) patient groups, via an echocardiography and the Framingham clinical criteria. The BNP was measured with a Triage$^{\circledR}$ kit. Both the clinical and echocar-diography profiles were analyzed. Results : The mean age of the patients was 62.8 years, with 49.0% males. The control group included 661, the SHF group 475 and the DHF group 287 patients. In the control group, the mean BNP level was 31.5$\pm$24.0 pg/mL, with the BNP level in the women higher than in the men (28.0$\pm$23.8 vs. 34.9$\pm$23.7 pg/mL, p=0.041). The SHF patients group had significantly higher BNP levels than the other groups (p=0.008). In the patients with SHF, the BNP levels, according to the NYHA grade, showed significant differences (I: 169.3$\pm$138.7, II: 91.1$\pm$231.4, III: 780.1$\pm$698.3 and IV: 1078.9$\pm$946.2 pg/mL, p=0.009). In the patients with diastolic dysfunction (n=787) according to the diastolic dysfunction, the BNP levels, showed significant differences (relaxation abnormality: 08.2$\pm$78.2, pseudo-normal: 419.0$\pm$109.8 and restrictive physiology: 510.4$\pm$231.6 pg/mL, p=0.009). The accuracy in the BNP level when separating the SHF from the control patients was 0.98 (AUC=0.98), with 92.5% sensifivity and 86.1% specificity at a cut-off of 108 pg/mL. Conclusions : The levels of blood BNP were present in various ranges according to the clinical situation and extent of heart failure.

Keywords

References

  1. Orn S, Dickstein K. Neurohormonal inhibition in heart failure, is there no limit? Eur Heart J 2003;24:1705-6. https://doi.org/10.1016/S0195-668X(03)00392-0
  2. Ryu KH, Han SW, Chae SC, Lee JH, Oh BH, Lee MM, et al. Multicenter analysis of clinical characteristics and prognostic factors of patients with congestive heart failure in Korea. Korean Circ J 2003; 33:629-34.
  3. Stevenson LW, Perloff JK. The limited reliability of physical sign for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8. https://doi.org/10.1001/jama.261.6.884
  4. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
  5. Devereux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension 1987;9:II97-104.
  6. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347: 161-7. https://doi.org/10.1056/NEJMoa020233
  7. Muders F, Kromer EP, Griese DP, Pfeifer M, Hense HW, Riegger GA, et al. Evaluation of plasma natriuretric peptides as marker for left ventricular dysfunction. Am Heart J 1997;134:442-9. https://doi.org/10.1016/S0002-8703(97)70079-6
  8. Kwon SH, On YK, Han DH, Lee SC, Jo YH, Lee NH, et al. Usefulness of B-type natriuretic peptide in congestive heart failure. Korean Circ J 2003;33: 695-700.
  9. Shin HS, Sung KC, Jung CH, Kim BS, Kang JH, Lee MH, et al. B-type natriuretic peptide blood concentrations in differential diag-nosis of dyspnea and its association to 6 minute walk. Korean Circ J 2003;33:302-10. https://doi.org/10.4070/kcj.2003.33.4.302
  10. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure. N Eng J Med 1971;285:1441-6. https://doi.org/10.1056/NEJM197112232852601
  11. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, Lee SW. Progression of systolic abnormalities in patients with 'isolated' diastolic heart failure and diastolic dysfunction. Circulation 2002;105:1195-201. https://doi.org/10.1161/hc1002.105185
  12. Friedl W, Mair J, Thomas S, Pichler M, Puschendorf B. Natriuretic peptides and cyclic guanosine 3’, 5’-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart 1996;76:129-36. https://doi.org/10.1136/hrt.76.2.129
  13. Kazanegra R, Cheng V, Gracia A, Krishnaswamy P, Gardetto N, Clopton P, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressure in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-9. https://doi.org/10.1054/jcaf.2001.23355
  14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82. https://doi.org/10.1016/S0735-1097(02)02059-4
  15. Cheng V, Kazanerga R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37:386-91. https://doi.org/10.1016/S0735-1097(00)01157-8
  16. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Ohnishi M, et al. High level of plasma BNP at discharge is an independent risk factor for mortality and morbidity in patients with congestive heart failure. J Am Coll Cardiol 1999;192A:1140-3.
  17. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Cardiol 2001;37:379-85. https://doi.org/10.1016/S0735-1097(00)01156-6
  18. Cabanes L, Richaud-Thiriez B, Fulla Y, Heloire F, Vuille mard C, Weber S, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001;120:2047-50. https://doi.org/10.1378/chest.120.6.2047
  19. Choi HJ, Hwang SO, Jang YS, Kim H, Lee KH. The usability of blood BNP concentration for differentiating the patients with acute dyspnea. J Korean Soc Emer Med 2002;2:124.
  20. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, van Lente F, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964-6. https://doi.org/10.1161/01.CIR.0000106903.98196.B6
  21. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Bedside B-type natriuretic peptide in the emergency emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol 2003:41:2010-7.
  22. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74. https://doi.org/10.1067/mhj.2001.113215
  23. Maeda K, Tsutamota T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32. https://doi.org/10.1016/S0002-8703(98)70041-9